Thomas Smith
Stock Analyst at Leerink Partners
(1.97)
# 3,095
Out of 5,097 analysts
60
Total ratings
31.48%
Success rate
6.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Outperform | $42 | $17.11 | +145.47% | 1 | Dec 1, 2025 | |
| RAPT RAPT Therapeutics | Upgrades: Outperform | $16 → $37 | $36.47 | +1.45% | 3 | Sep 26, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $1.40 | -28.57% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $3.03 | +197.03% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $3.07 | +128.01% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $11.18 | +159.39% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $6.72 | +480.36% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $6.24 | +316.67% | 1 | Mar 25, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $138.72 | -85.58% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $852.04 | -48.95% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $79.54 | -54.74% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.54 | +175.59% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $27.54 | -23.75% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $32.47 | +38.59% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $12.74 | -52.90% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $5.99 | +0.17% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.60 | +728.78% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $13.49 | +26.02% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $27.27 | +134.69% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $17.37 | +302.99% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $1.64 | +1,485.37% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $35.40 | -66.10% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $28.92 | +1,283.13% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $21.34 | +274.88% | 2 | Dec 8, 2020 |
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $42
Current: $17.11
Upside: +145.47%
RAPT Therapeutics
Sep 26, 2025
Upgrades: Outperform
Price Target: $16 → $37
Current: $36.47
Upside: +1.45%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $1.40
Upside: -28.57%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $3.03
Upside: +197.03%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $3.07
Upside: +128.01%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $11.18
Upside: +159.39%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $6.72
Upside: +480.36%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $6.24
Upside: +316.67%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $138.72
Upside: -85.58%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $852.04
Upside: -48.95%
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $79.54
Upside: -54.74%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.54
Upside: +175.59%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $27.54
Upside: -23.75%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $32.47
Upside: +38.59%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $12.74
Upside: -52.90%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $5.99
Upside: +0.17%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.60
Upside: +728.78%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $13.49
Upside: +26.02%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $27.27
Upside: +134.69%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $17.37
Upside: +302.99%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $1.64
Upside: +1,485.37%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $35.40
Upside: -66.10%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $28.92
Upside: +1,283.13%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $21.34
Upside: +274.88%